[1]Williams R. Global challenges in liver disease. Hepatology,2006,44(3):521-526. [2]Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology,2013,57(4):1333-1342. [3]WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization,2018,https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/. [4]中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版).实用肝脏病杂志,2019,23(1):33-52. [5]Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology,2005,42(4):962-973. [6]Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology,2014,59(1):318-327. [7]Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol,2017,2(3):161-176. [8]Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology,2015,61(1):77-87. [9]苏迎盈, 刘慧鑫, 汪宁. 中国丙型肝炎病毒基因型分布. 中华流行病学杂志,2013,34(1):80-84. [10] Du G, Li X, Musa TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol,2019,91(3):401-410. [11] Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol,2014,29(3):545-553. [12] Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat,2011,18(11):745-759. [13] Lee MH, Yang HI, Lu SN, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol,2010,28(30):4587-4593. [14] Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol,2009,24(3):336-345. [15] Fu Y, Qin W, Cao H, et al. HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China:phylogeographic analyses. PLoS One,2012,7(1):e28006. [16] Zhang Z, Yao Y, Wu W, et al. Hepatitis C virus genotype diversity among intravenous drug users in Yunnan province, southwestern China. PLoS One,2013,8(12):e82598. [17] Zhang C, Wu N, Liu J, et al. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. PLoS One,2011,6(2):e16817. [18] Liu J, Zhang C. Phylogeographic analyses reveal a crucial role of Xinjiang in HIV-1 CRF07_BC and HCV 3a transmissions in Asia. PLoS One,2011,6(8):e23347. [19] Tao J, Liang J, Zhang H, et al. Themolecular epidemiological study of HCV subtypes among intravenous drug users and non-injection drug users in China. PLoS One,2015,10(10):e0140263. [20] Ju W, Yang S, Feng S, et al. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J,2015,12:109. [21] Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am,2015,44(4):717-734. [22] Wu N, Rao HY, Yang WB, et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl),2020,133(3):253-261. |